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Abstract 
Alzheimer’s disease (AD) pathology relevant proteins tau and beta-amyloid (Aβ) exist as an 
array of post-translationally modified and conformationally altered species with varying 
abundance, solubility and toxicity. Insoluble neurofibrillary tau tangles and Aβ plaques are 
end-stage AD hallmarks, yet may carry less disease significance compared to soluble species. 
At present, it is unclear how soluble and insoluble tau and Aβ relate to each other as well as 
to disease progression. Here, detergent soluble and insoluble fractions generated from post-
mortem human temporal lobe samples (Brodmann area 21) were probed for tau and Aβ 
markers in immuno-dot assays. Measures were quantified according to diagnosis (AD cf. 
Non-AD), neuropathological severity, and correlated with disease progression (Braak 
stages).  All markers were elevated within AD cases cf. non-AD controls (p<0.05) 
independent of solubility. However, when considered according to neuropathological 
severity, phospho-tau (detected via CP13 and AT-8 antibodies) was elevated early within the 
soluble fraction (p<0.05 intermediate cf. low severity) and emerged only later within the 
insoluble fraction (p<0.05 high cf. low severity). In contrast, PHF1 phospho-tau, TOC reactive 
tau oligomers and amyloid markers rose within the two fractions simultaneously. 
Independent of solubility, cognitive correlations were observed for tau makers and for 
fibrillary amyloid (OC). In contrast only soluble total Aβ was significantly correlated with 
intellectual impairment. Following the exclusion of end-stage cases, only soluble total Aβ 
remained correlated with cognition. The data indicate differential rates of protein 
aggregation during AD progression and confirm the disease relevance of early emerging 
soluble Aβ species.  
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1. Introduction 
Senile (SP) and neuritic plaques (NP) composed of beta-amyloid (Aβ) together with 
intracellular tau-based neurofibrillary tangles (NFTs) constitute the neuropathological 
hallmarks of Alzheimer’s disease (AD). The spatial quantification and characteristic spread of 
NFTs (Braak stages; Braak and Braak, 1995) and SP (Thal phases; Thal et al., 2002), alongside 
plaque density have been consolidated into a widely-adopted scheme for post-mortem 
neuropathological assessment (see the ‘Consortium to Established a Registry for AD’, 
(CERAD); Boluda et al., 2014).  
Despite their utility in gauging AD related gross pathology, these hallmarks are not 
restricted to bona fide AD cases and can also emerge to a certain extent with age, often as 
subclinical neuropathology (see Spires-Jones et al., 2017, for review). For example, primary 
age related tauopathy (PART) cases present with modest AD-related Braak stage 
progression and mild cognitive impairment (MCI) in the absence of conventional Aβ 
pathology (Crary et al., 2014; Josephs et al., 2017). Similarly, post-mortem characterisation 
of non-demented individuals report a sub-population of cases in which substantial Aβ 
pathology is evident in the absence of significant cognitive impact, referred to as non-
demented high pathological controls (HPC; Mufson et al., 2016) or pathologically diagnosed 
preclinical AD (p-PreAD; Upadhaya et al., 2014). 
Such observations cast doubt on the causality of proteinaceous aggregates, particularly Aβ 
plaques, and their associations with cognitive impairment. Many post-mortem studies have  
reported a robust increase in SP and NP in AD cases, but indicate modest to no significant 
correlation between plaque load and cognitive deficits (Arriagada et al., 1992; Näslund et 
al., 2000; Giannakopoulos et al., 2003) or disease duration (Ingelsson et al., 2004). In 
comparison, greater agreement exists between NFT pathology and mental decline 
(Giannakopoulos et al., 2003; Markesbery et al., 2006).  
Nevertheless, given the well-established stereotypical emergence of NFTs (Braak and Braak, 
1995) as well as SP (Thal et al., 2002) and their invariable presence within AD pathology, 
such lesions are unlikely to be inconsequential. Conceptually, plaques and tangles may 
sequester more toxic yet less aggregated species into tightly bound, insoluble fibrils. This 
deposition may diminish their toxic potential and ubiquity, and reduce widespread neuronal 
damage whilst generating a secondary localised insult. It is equally plausible that specific 
subpopulations of deposited aggregations may retain a toxic potential whilst others are 
rendered inert (Ladiwala et al., 2010+ 2011; Cowan et al., 2015). Indeed, animal models 
have demonstrated that the presence of NFTs within neurons is neither conducive to 
physiological failure (Kuchibhotla et al., 2014) nor to cognitive impairment (Santacruz et al., 
2005). 
Naturally, post-mortem histopathological determination of protein aggregates relies on end 
stage pathologies and utilises broad measures of quantification which may fail to account 
for the heterogeneity of insoluble and soluble structures. This limits our causal 
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understanding of pathological processes and the modifications driving Aβ and tau to adopt 
mature aggregated depositions. 
Both Aβ and tau share common schemes of aggregation, as monomers form prefibrillar 
oligomers followed by fibrillary intermediates or oligomers, which are incorporated into 
protofilaments prior to maturation in filamentous SPs and NFT aggregates (reviewed in 
Serpell, 2000; Kuret et al., 2005; Ruggeri et al., 2015). The aggregation process is closely 
linked to the adoption of β-sheet conformations, which results in decreased solubility in 
aqueous solutions, with higher order assemblies soluble only in solvents such as 
Hexafluoroisopropanol (HFIP) and formic acid (Burdick et al., 1992; Halverson et al., 1990). 
The generation of conformation-specific antibodies raised against tau (MC-1 (Jicha et al., 
1997); TOC1 (Patterson et al., 2011) and Aβ (A11 and OC, Kayed et al., 2007 ) in various 
states of aggregation have helped to validate multiple intermediate Aβ and tau species as 
immune-reactivity distinct.  Specifically, TOC1 recognises an exposed epitope within tau 
which is natively accessible only upon oligomerisation (Ward et al., 2014). Accordingly, a 
number of studies have shown early stage elevations in TOC1 reactivity within tauopathy 
mouse models (Ward et al., 2014) and human tissue (Patterson et al., 2011 and Koss et al., 
2016).  The amyloid-selective OC antibody recognises a common and conserved 
conformation within all fibril amyloid proteins, independent of amino acid sequence (Kayed 
et al., 2007). In relation to Aβ, the OC epitope is rapidly formed from isolated soluble 
monomers and present within low weight fibrillar oligomers prior to formation of more 
mature Thioflavin T positive fibrils, themselves also OC reactive (Coalier et al., 2013). 
Across the spectrum of tau and Aβ assemblies a profile of graded toxicity is emerging. 
Soluble prefibrillar oligomers are suggested as most toxic (Walsh and Selkoe, 2007, Lasagna-
Reeves et al., 2011; Castillo-Carranza et al.; 2014; Cox et al., 2016) and strongly index 
cognitive decline (Koss et al., 2016). However, both soluble and insoluble fibrillary oligomers 
are also reported to exert a significant level of toxicity (Ladiwala et al., 2010). In addition, 
non-toxic soluble and insoluble, so-called off-pathway aggregates have also been reported 
(Cowan et al., 2015, Ladiwala et al., 2010 +2011; Sharoar et al., 2012; Bieschke et al., 2011).  
In biological tissues the isolation of Aβ and tau configurations are commonly achieved via 
multistep fractionation exploiting their variable degree of solubility. Monomeric and low 
weight prefibrillary species can be extracted within aqueous buffers with or without mild 
non-ionic detergents, whilst larger aggregates can be solubilised in strong denaturing agents 
such as formic acid or isolated by their insolubility in a 1% sarkosyl solution (see Rostagno 
and Ghiso et al., 2009; Julien et al., 2012 for review). 
Prior work suggests that even within middle-aged non-AD cases as much as 30-45% of total 
Aβ can be isolated from a detergent insoluble fraction by formic acid, the percentage rising 
to 97-99% in AD brains (Wang et al., 1999). The overlap of gross insoluble Aβ levels between 
AD and control cases has led to a weak predictive value for AD diagnosis (Näslund et al., 
2000; Tremblay et al., 2007). Despite soluble Aβ levels representing only 1-2% of total Aβ 
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within the AD brain a more robust correlation with disease severity has been reported 
(McLean et al., 1999, Wang et al., 1999; Koss et al., 2016).   
In contrast to Aβ, the vast majority of tau protein can be isolated within aqueous or 
detergent soluble fractions. In non-AD cases, as much as 97% of tau can be recovered from 
the soluble fraction, whilst in AD this is considerable lower (~50%) due to the accumulation 
of insoluble aggregates (Mukaetova-Ladinska et al., 1993; Tremblay et al., 2007; Han et al., 
2017). Insoluble tau isolated from human AD brains is 3-4-fold higher compared to non-AD 
brains (Hanger et al., 1991; Ksiezak-Reding et al., 1992) and levels within temporal and 
parietal regions are robustly elevated mirroring the regional burden of NFTs. This acts as a 
good indicator of disease progression, correlating with Braak staging as well as CERAD 
scores and various cognitive measures (Mukaetova-Ladinska et al., 1993; Tremblay et al., 
2007). Nevertheless, soluble tau species also demonstrate increased phosphorylation at 
many of the same sites observed in insoluble AD tau (Matsuo et al., 1994, Zhou et al., 2006 
and Koss et al., 2016). Investigations into presumed toxic tau species have identified a 
number of immunological distinct conformations (Jicha et al., 1997) as well as prefibrillar 
and fibrillary aggregation states (Patterson et al., 2011; Lasagna-Reeves et al., 2012) in 
addition to phospho-tau species. However, it remains unclear how soluble tau species relate 
to the hyperphosphorylated, insoluble aggregates. 
Despite the growing number of identified molecular entities comprising tau and Aβ 
pathology and their abundance in human AD brains, few studies have sought to determine 
the emergence of such species within the context of one another. Following on from our 
previous characterisation of soluble AD pathology within the temporal lobe of human AD 
cases we here present further data assessing both soluble and insoluble tau and Aβ species 
in relation to AD diagnosis, neuropathological severity and cognitive decline.  Moreover, we 
sought to evaluate OC reactive amyloids as a potentially improved or additional measure of 
pathology.  
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2. Results 
2.1 Detection of distinct soluble and insoluble immunoreactive species   
To preserve the native conformations of extracted soluble species and to avoid size based 
exclusion issues during SDS/PAGE, dot-blots were used for the detailed quantification of 
soluble cf. insoluble tau and Aβ species. Prior to this, the extraction of distinct tau and Aβ 
configurations within the two fractions was confirmed via Western blotting (Fig. 1). Tau 
species isolated within the soluble fraction when resolved on SDS page migrated as defined 
protein bands compared to smears obtained from the insoluble fraction. This was particular 
apparent for the pan-tau antibody HT-7 (Fig. 1A,) as well as phospho-tau antibody CP13 (Fig. 
1B), although some smearing was evident upon applying enhanced contrast (see Suppl. Fig. 
1). Interestingly, the distinction between soluble and insoluble tau species was not as 
evident with PHF1 reactive tau species, which migrated across a broad range of molecular 
weights (25->220kDa) independent of fraction (Fig. 1C).  
Soluble Aβ detected with MOAB-2 was evident across the length of the gel (Fig. 1D). Despite 
only weak immunoreactivity for monomeric Aβ (~4 kDa, see Suppl. Fig. 1D for enhanced 
contrast), more intense reactivity was concentrated around the 35-60 kDa region and within 
material retained within the loading wells. The range of immunoreactivity within the soluble 
fraction differed from the predominate detection of 40 to 220 kDa migrating MOAB-2 
reactive material in the insoluble fraction.  Western blot analysis of Aβ with pan Aβ antibody 
6E10 robustly detected a 4 kDa reactive band corresponding to the monomeric peptide in 
both soluble and insoluble fractions (see Suppl. Fig. 2). 
 
Under SDS page conditions only limited OC reactive species were detected in both the 
soluble and insoluble fraction. It is notable that due to the conformational nature of the 
antibody, only those aggregates which are not denatured upon SDS exposure would remain 
in a detectable configuration (Coalier et al., 2013). Nevertheless, an increased OC signal 
(two bands evident at 40-60 kDa) was seen in AD cases when compared to non-AD controls 
within the soluble fraction as well as in the mid-range smears from the insoluble fraction 
(Fig. 1E).      
For most blots (insoluble fraction for all antibodies and soluble PHF1 fraction) little to no 
immunoreactivity was evident in non-AD cases for optimised exposure settings. Following 
contrast enhancement of blots where signals from AD cases were saturated, weak signals 
emerged in non-AD samples in most cases (see Suppl. Fig. 1). 
Immunoreactivity in both soluble and insoluble fractions for all antibodies were 
subsequently quantified in dot blots with ECL signals being normalised to total protein as 
established via a Coomassie membrane stain (see Suppl. Fig. 3 for example Coomassie 
stained membrane images). 
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2.2 Tau 
Total tau dot blot signals from isolated soluble and insoluble fractions demonstrated a 3 and 
4 fold increase in immunoreactivity, respectively, in accordance with AD diagnosis 
(p<0.0001, for both Fig. 2 i+ii). Increased HT-7 reactivity in both fractions was evident 
between high neuropathology cases compared to those classed as low neuropathological 
cases (p<0.001, Fig. 2 iii), yet only in the soluble fraction was an increase between 
intermediate and high pathology cases observed (p<0.001, Fig. 2 iii). 
Correlations of HT-7 immunoreactivity with individual Braak staging reported an increased 
correlative strength for soluble tau compared to the insoluble fraction (r=0.72; p<0.01 
compared to r=0.57; p<0.01 for soluble and insoluble measures, respectively, Fig. 2 iv). For 
both severity and individual Braak stage classification, high levels of variability may have 
prevented detection of a significant increase relative to pathology free cases (Br0) within 
the insoluble fraction, HT-7 immunoreactivity differed reliably only between Br6 and Br0 
cases (p<0.05).  Levels of soluble and insoluble tau were modestly related within individual 
cases (Spearman’s correlation, r=0.48, p<0.0001). Further statistical tests via a 2-way 
ANOVA with Braak stage and fraction as factors reported a significant effect only of Braak 
stage (p = 0.0001). As floor level effects at Braak stage 0 and ceiling level effects at Braak 
stage 5-6 may influence these statistical interrogations, a further 2-way ANOVA was run 
including only data from Braak stages 2-4. These stages represent the phase of progressive 
neuropathology within the temporal lobes and hence the point of conversion from non-AD 
and AD. However, again only a significant effect of Braak stage (p<0.01) was reported. Full 
details and associated F values for 2-way ANOVA are given in Suppl. Table 1.  
2.3 Phospho-tau 
The phospho-tau antibody AT8 is universally employed for immunohistological Braak 
staging. Both soluble and insoluble tau pathology can be detected via AT8 in the form of 
pre-tangle pathology and NFT containing neurons, respectively. Accordingly, comparative 
dot blots demonstrated increased AT8 reactivity in both fractions (p<0.0001 for both, Fig. 3A 
i+ii).  
AT-8 immunoreactivity was consistently detected in all cases within the soluble fraction 
independent of diagnosis, and only one non-AD case was without discernible 
immunoreactivity in the corresponding insoluble fraction.   
In line with the assumption that soluble pre-tangle neurons represent the precursors of 
mature NFTs, elevations from low neuropathology cases in AT8 reactive tau were more 
readily apparent from the soluble (low cf. intermediate, p<0.01 and low cf. high, p<0.001; 
Fig. 3A iii) than in the insoluble fraction (low cf. intermediate, p>0.05, low cf. high, p<0.001). 
This differentiation was particularly apparent for Braak 4 (Braak stage 4 vs Braak stage 0 
cases: p<0.05, Fig. 3A iv), preceding the later stage rise in insoluble AT8 reactive tau (Br6, 
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p<0.05). Both fractions reported a high level of correlation across Braak staging, (r=0.81, 
p<0.01) cf. insoluble AT8 data (r=0.75, p<0.01) as well as between each other (r=0.62, 
p<0.0001).  
As observed for AT8, CP13 reactive insoluble tau was detected in the majority of samples 
(93% of non-AD cases and 100% of AD cases). Insoluble CP13 reactivity was elevated in a 
diagnosis specific manner (p<0.01; Fig. 3B i+ii), yet only significantly raised in the high 
(p<0.001; Fig. 3B iii) but not intermediate neuropathological cases relative to low pathology 
cases (p>0.05). This late stage elevation was in contrast to soluble CP13 tau which 
demonstrated increased immunoreactivity across all severity groups (low cf. intermediate 
p<0.01, low cf. high p<0.001, Fig. 3B iii) and may suggest CP13 as having greater sensitivity 
for earlier soluble phospho-Tau species (Koss et al., 2016).  
In line with correlations observed for AT8, measurements of CP13 phospho-tau aligned with 
progressive Braak stages (r=0.78 and r=0.65, for soluble and insoluble respectively, p<0.01 
for both; Fig. 3B iv). CP13 reactivity between fractions from each case also strongly 
correlated (r=0.68, p<0.0001). High variability prevented any individual Braak stage from 
reaching significance relative to Braak stage 0 for data from the insoluble fraction, in 
constrat to soluble fraction with was already elevated by Braak stage 2. 
In contrast to the profile of CP13 and AT8, insoluble PHF1 reactive tau demonstrated a 
significant elevation not only dependent on AD diagnosis (p<0.0001; Fig. 3C i+ii) but also 
between intermediate and low pathology cases as well as between high and low 
pathological cases (p<0.001; Fig. 3C iii). Equally, the correlation of progressive 
phosphorylation at the PHF1 epitope with Braak stage was comparable for both soluble and 
insoluble measurements (r=0.83; p<0.01; Fig. 3C iv), strongly correlated with each other 
(r=0.82, p<0.0001), and reached significance from Braak 0 cases at Braak stage 4 and 5, 
respectively (p<0.05, for both).  Although PHF1 immunoreactivity reported increased 
sensitivity for intermediate stage pathology as well as the greatest correlation with Braak 
staging, when considered alongside AT8 and CP13, a number of samples for both non-AD (7 
out of 20, 35%) and AD (2 out 18, 11.11%) were without detectable reactivity for PHF1 in 
the insoluble fraction. 
All phospho-specific antibodies reported a significant effect of Braak stage (p<0.01) 
following a 2-way ANOVA across all Braak stages. However, only PHF-1 yielded both an 
interaction (p<0.05) as well as a significant effect of fraction (p<0.001), presumably due to 
the magnitude of change between soluble and insoluble preparations.  Bonferroni post-tests 
indicated that the significance of fraction was largely driven by Braak stage 6 (p<0.001).  
Focusing on the progressive phase of pathology (Braak stage 2-4), all phospho-tau 
antibodies reported significant effects of Braak stage (p<0.001) as well as fraction (p<0.05) 
and an interaction for CP13 and AT8 (p<0.0001). Post-tests revealed that differences at 
Braak stage 4 drove the significance of fraction (p<0.0001) for both CP13 and AT8. Full 
details are given in Suppl. Table 1.    
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Given that post-mortem interval (PMI) may alter protein phosphorylation, i.e. proteins may 
become dephosphorylated following death, all phospho-tau values were investigated for a 
significant relationship with PMI duration. No significant correlation was observed between 
any phospho-tau marker or indeed any other marker examined and hours prior to post-
mortem, for either soluble or insoluble fractions.  
 
2.4 Oligomeric Tau 
TOC1 immunoreactivity was detected in both soluble and insoluble fractions. Although this 
antibody preferentially binds to prefibrillar conformations, assumed to be largely soluble in 
aqueous solutions, end labelling of more mature insoluble tau fibrils has also been observed 
(Patterson et al., 2011; Ward et al., 2014). 
Insoluble reactivity was significantly raised in AD cases (p<0.05, Fig. 4 i+ii), and elevated in 
late stage high pathological cases compared to those with low neuropathology (p<0.001 Fig. 
4 iii). These findings are largely in line with observations from the soluble fraction (as 
previously reported Koss et al., 2016). When correlated with Braak stage, soluble and 
insoluble TOC1 measures were of comparable strength (r=0.61 cf. 0.60, respectively, p<0.01, 
Fig. 4 iv). Again, as for PHF1 a strong correlative agreement was observed between soluble 
and insoluble levels of TOC1 (r=0.78, p<0.0001). However, insoluble TOC1 reactive material 
reported a significant elevation from Braak 0 cases only at the last pathological stage (Br 6; 
p<0.05). A 2-way ANOVA across either all Braak stages or Braak stage 2-4 reported only a 
significant effect of Braak stage (p<0.01, see Suppl. Table 1).   
 
2.5  Aβ 
Quantification of monomeric Aβ using 6E10 failed to detect significant differences between 
groups according to diagnosis or severity classifications within the insoluble lysates, despite 
elevations in the soluble fraction (see Suppl. Fig. 2 i-iii. In light of the previously reported 
technical considerations related to quantification of Aβ via Western blotting with the 6E10 
antibody (Koss et al. 2016), we here quantified total Aβ using the MOAB-2 antibody which 
does not cross-react with APP or non-Aβ metabolites (Youmans et al., 2012). Quantification 
via dot blot reported robust immunoreactivity in all cases, independent of fraction (Fig. 5 i). 
Quantification of total Aβ within the insoluble fraction was significantly elevated across AD 
diagnosis (p<0.05, Fig. 5 ii), yet only an overall trend within severity classifications (p=0.075, 
Fig. 5 iii) was observed no correlation across individual Braak stages was reported (p>0.05). 
When compared within individual cases a modest agreement between soluble and insoluble 
levels was reported (r=0.49, p<0.001). The large degree of overlap between diagnosis 
groups as well as within severity classifications quantified in the insoluble fraction is in 
contrast to the improved separation of signal strength seen in the soluble fraction, 
particularly between diagnosis groups (as previously reported Koss et al., 2016, non-AD cf. 
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AD, p<0.0001, overall severity effect, p<0.0001 and correlation with Braak stage, r=0.7, 
p<0.001).  Potentially influenced by the high variability of signal obtained in the insoluble 
fraction, neither Braak stage (p>0.05) or fraction (p>0.05) were reported as significant 
variables in 2-way ANOVA, both when considered across the entire Braak staging scale and 
when limited to progressive pathological stages for the temporal lobe (Braak stages 2-4). 
See Suppl. Table 1 for details. 
 
2.6 Fibrillary amyloid 
We next investigated the amino acid sequence independent fibrillary amyloid antibody, 
previously shown to react with toxic fibrils comprised of amyloids (Ladiwala et al., 2011). 
Accordingly, OC immunoreactivity in both soluble and insoluble sample fractions was 
dependent on diagnosis (Fig. 6 i+ii; p<0.0001 for both), as well as neuropathology severity 
(Fig. 6 iii; overall p<0.001, for both). Significance across severity classifications was 
principally driven by the increased signal detected in high severity cases compared to those 
with low levels of pathology (p<0.001 for both), although specifically in the soluble 
fractionation, a further distinction between intermediate and high neuropathology was also 
reported (p<0.05). Equally, correlation of OC immunoreactivity with Braak staging was 
greater for the soluble fraction (Fig. 6 iv; r=0.68, p<0.01; insoluble: r=0.58, p<0.01).  
However, a robust relationship between soluble and insoluble quantification was evident 
(r=0.64, p<0.0001) and regardless of solubility, a prominent increase in the levels of OC 
reactive material was apparent in cases determined as Braak stage 4 cf. Braak stage 0 
(p<0.05).   Subsequent tests utilising 2-way ANOVA reported Braak stage as the only 
significant variable (p<0.001) when considered either across all Braak stages or when limited 
to Braak stages 2-4 (See Suppl. Table 1). 
2.7 Inter-marker correlations (Tau and Amyloid) 
In line with the beta-amyloid cascade hypothesis, it can be speculated that an accurate 
measurement of Aβ pathology, either from within a soluble or insoluble fraction, should 
correlate to a degree with the level of tau pathology within a particular brain region. Whilst 
itself not evidence for causality, such a relationship would serve to support the validity of 
the hypothesis. 
Strikingly, correlations between tau and amyloid markers revealed a robust pattern such 
that only soluble Aβ as established by MOAB-2 reported a degree of correlation with each of 
the markers of tau pathology from both fractions (Table 1). In contrast, measures of 
insoluble MOAB-2 reactivity failed to correlate significantly with the any tau measures. OC-
immunoreactivity established from the soluble fraction demonstrated comparative 
correlations with tau pathology in relation to those observed with soluble MOAB-2 signals. 
Furthermore, moderate correlations were reported for insoluble OC measures and the 
majority of tau markers.  
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2.8 Pathological marker association with disease progression and cognitive decline  
The majority of measures demonstrated some degree of correlation with pathological 
scores of disease progression including Braak staging (as reported above), but also with 
CERAD scores of plaque density (Table 2).  All tau markers, both soluble and insoluble, 
reported relatively strong correlations with CERAD neuritic plaque score. Surprisingly, 
soluble but not insoluble (MOAB-2 reactive) Aβ correlated with the CERAD neuritic plaque 
score. Nevertheless, OC yielded a strong correlation with CERAD scores independent of 
fraction.   
Measures of insoluble tau pathology (phosphorylation and oligomeric) largely mirrored the 
robust correlations previously reported between soluble tau pathology and cognitive scores 
(Koss et al., 2016).  Total measures of insoluble tau via HT-7 failed to correlate with scores of 
any cognitive test examined here. Of the pathological markers, insoluble AT8 demonstrated 
the weakest correlation with cognition, with only modest relationships reported for MMSE 
and global CDR scores.   
Comparable to the relationship between tau pathology and cognition in both fractions were 
only the data obtained for OC-reactive amyloid but not for measures of total Aβ as insoluble 
Aβ largely failed to correlate with cognitive scores (Table 2). As previously reported, soluble 
total Aβ pathology tracked strongly with disease progression and cognitive impairment 
(Koss et al., 2016 and Table 2).  
To further resolve relations with insight into the earlier stages of the disease and in a bid to 
limit the impact of end stage data points, this analysis was also conducted across Braak 
stage 0-4, omitting Braak 5 and 6 pathology cases (see Table 2: values provided in brackets). 
The resulting correlations can be summarised as follows: 1. Measures of total tau failed to 
correlate with either Braak or CERAD neuropathological scores as well as any cognitive 
measures 2. Phospho- and oligomeric tau measures largely failed to report significant 
correlations with scales of cognitive assessment, despite preserved correlations with Braak 
staging; 3. Except for soluble total Aβ where correlative strength was largely unaffected, a 
similar loss of significance was observed for all other Aβ markers.  
 
3. Discussion 
This study reports on the relationship of soluble and insoluble tau and amyloid pathology 
from human temporal lobe samples in the context of neuropathological and cognitive 
measures of AD disease progression. Here, the direct comparison of soluble and insoluble 
AD markers largely supports and extends our previous findings that soluble pathology better 
tracks disease status and mental decline (Koss et al., 2016). Interestingly, two distinct 
profiles of solubility were observed: most markers displayed a coordinated rise of 
immunoreactivity in both soluble and insoluble preparations, but specifically, phospho-tau 
markers appeared to follow a lag phase of deposition, rising first in the soluble fraction. In 
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addition, the quantification of sequence-independent insoluble amyloid fibrils provided an 
improved measure of pathology, offering stronger correlations with disease progression as 
well as intellectual impairment compared to total levels of insoluble Aβ. Nevertheless, 
measures of tau pathology remained the strongest correlates of all aspects of the disease, 
when considered across all Braak stages, however only soluble total Aβ remained correlated 
with disease progression and impairment when end-stage cases were excluded.   
3.1 Associations of soluble vs insoluble Tau species  
Given that the quantification of AT8 histological immunoreactivity under the scheme of 
Braak staging is the principle measure of AD progression (Braak and Braak, 1995), it is 
unsurprising that multiple indices of tau pathology strongly tracked many measures of 
disease severity. Nevertheless, divergence amongst these tau markers in relation to 
progressive elevation and emergence within the insoluble fraction was evident. 
All tau markers in the soluble fraction except for the oligomeric tau antibody were elevated 
in intermediate and high neuropathology cases compared to low controls. In contrast, no 
rise was seen in the intermediate cases for insoluble measures of total tau, CP13 and AT8 
phospho-tau antibodies. The temporal emergence of insoluble tau pathology is in 
accordance with pathology of the superior temporal lobes, with NFTs at Braak stage 4 /5 
(Alafuzoff et al., 2008) and the preceding elevation of soluble phospho-tau in line with  the 
presence of pre-tangle neurons prior to the formation of mature aggregation (Braak et al., 
2011).  Indeed, supported by the detection of CP13 positive neurons which otherwise 
appear normal, even in non-demented cases (Kimura et al., 1996) we have previously 
reported that the CP13 phospho-epiptope may be an earlier marker of tau pathology (Koss 
et al., 2016).  
Although single endpoint post-mortem studies cannot track progression of pathological tau 
species from soluble to insoluble compartments, our hypothesis is strongly supported by the 
age dependent translocation of specific phosphorylated tau species into insoluble 
aggregates in animal models (Delobel et al., 2008). Furthermore, the delayed deposition of 
insoluble tau species has been determined in vitro (Friedhoff et al., 1998). The lag phase for 
the production of insoluble tau species is in part a result of the net positive charge of the 
molecule, which makes the adoption of ordered protein structures such as β-sheets 
unfavourable, and requires conformational changes to an aggregation competent state (see 
Nizynski et al., 2017 for review).  
Tau fibrillisation may require site-specific phosphorylation, as indicated here by measures of 
PHF1 reactive tau, which suggests differential kinetics compared to CP13 and AT8 reactive 
tau. PHF1 immunoreactivity rose simultaneously across both soluble and insoluble fractions 
and may imply that the phosphorylation of PHF1 residues (serine 396 and threonine 404) 
are facilitatory to the aggregation of insoluble tau species. Many pseudo-phosphorylation 
studies support differential promotion of tau aggregation via site directed phosphorylation, 
such that C-terminal phosphorylation promotes aggregation, whilst N-terminal 
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phosphorylation may inhibit or be benign for aggregation (Iqbal et al., 2009; Martin et al., 
2011 for reviews). Accordingly, phospho-mimetic mutations at the PHF-1 epitope of tau 
displays enhanced aggregation kinetics in a number of in vitro assays (Ding et al., 2006; 
Abraha et al., 2000; Haase et al., 2004). Post mortem histological studies further support a 
prominent role for PHF1 in tau aggregation, i.e. early tau aggregates are more frequently 
labelled with PHF1 compared to AT8 (Mondragón-Rodriguez et al., 2014). Equally, sampling 
of the parahippocampal cortex reported on a subpopulation of PHF-1 positive yet AT-8 
negative NFTs (Merino-Serrais et al., 2013). 
An increased propensity for insoluble aggregation may also account for the parallel increase 
in soluble and insoluble oligomeric (TOC1) tau species in relation to Braak stages. Of note, 
significant elevations in TOC1 reactivity were only evident when comparing high to low 
neuropathological cases. Primarily reported to label dimeric tau species when resolved 
under non-denaturing conditions, electron micrographs have demonstrated the binding of 
TOC1 to a mixture of irregular shaped oligomers and the terminal ends of short filaments 
(Patterson et al., 2011; Ward et al., 2014). The end labelling of filaments may be indicative 
of TOC1 positive oligomers undergoing seeding and aggregation by oligomeric-nucleated 
conformation induction (Gerson and Kayed, 2013). Low-weight tau oligomers 
(dimers/trimers) are capable of promoting monomeric tau to form similar oligomers hence 
leading to fibrillization following prolonged incubations (Lasagna-Reeves et al., 2010+2012). 
However, previous characterisation of TOC1 reactive tau dimers have not been 
demonstrated to form fibrils without additional cofactors in vitro (Patterson et al., 2011). In 
human tissue TOC1 immunoreactivity did not co-localise with Thioflavin-S and Ab39 
staining, two markers of mature tau aggregation (Ward et al., 2014). If indeed integrated 
into fibrils, TOC1 reactive structures may be masked within the aggregates and only emerge 
after solubilisation in formic acid. Nevertheless, soluble TOC1 positive tau species closely 
tracked the abundance of insoluble tau species hence offering support for the putative 
integration of TOC1 positive dimers into fibrils or other insoluble structures. 
 
3.2 Measures of Amyloid 
As with PHF1 and TOC1 reactive tau species, both total Aβ as well as fibrillary amyloid 
detected by MOAB-2 and OC antibodies, respectively, also demonstrated a progressive and 
parallel increase in the both fractions. Correlations suggest aggregation kinetics in line with 
in vitro studies where Aβ peptides readily aggregate at low concentrations (nM) in the 
absence of any co-factors (Vandersteen et al., 2012). Similarly, the rapid formation of OC 
competent oligomers and their maturation into OC reactive fibrils has been reported to 
occur in preparations of isolated Aβ42 monomers (Coalier et al., 2013).   
Consistent with many other studies, levels of both soluble and insoluble Aβ were elevated in 
AD cases compared to controls (McLean et al., 1999; Ingelsson et al., 2004; Tremblay et al., 
2007). However, in contrast to the soluble fraction, insoluble Aβ (MOAB-2) measures 
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displayed a large degree of overlap between diagnosis groups and across neuropathological 
severity.  Both histological (Price and Morris, 1999; Braak et al., 2011) and biochemical 
assessments (Tremblay et al., 2007; Maarouf et al., 2011) of post-mortem tissue reported 
high levels of variability, even many control cases presented with high levels of insoluble Aβ 
reactive material.   
Improved diagnostic specificity, as offered by soluble MOAB reactive Aβ, was similarly 
observed by soluble OC reactive amyloid. Furthermore, OC quantification within the 
insoluble fraction demonstrated a reduced degree of overlap for both diagnosis and 
neuropathological severity stratification and improved correlative strength relative to 
disease progression and cognitive decline.  The sequence independent OC antibody has 
been demonstrated to bind to a number of proteins, including Aβ, α-synuclein and islet 
amyloid polypetide but not tau aggregates such as NFTs at least within histological 
preparations (Kayed et al., 2007). The majority of immunoreactivity within the current 
samples therefore likely derives from interactions with Aβ. Nevertheless, given the 
heterogeneity of AD pathologies (McAleese et al., 2017; Walker et al., 2015) and the impact 
of technical factors related to tissue homogenisation, it cannot be ruled out that tau, α-
synuclein and or TAR DNA-binding protein 43 may also have contributed to the overall 
signal. Previous work has reported a significant elevation in soluble OC reactive fibrillary 
oligomers in various regions of AD affected brains (Tomic et al., 2009) as also observed here. 
In the present study, we extend these findings reporting a similar increase in insoluble OC 
reactive material and strong correlative relationships with Braak and CERAD scores for both 
soluble and insoluble OC fibrils. Histological examination of AD mouse models suggests that 
the accumulation of soluble and insoluble OC reactive material is closely associated with 
plaque formation (Liu et al., 2015). The improved separation cf. diagnosis and 
neuropathological severity observed with insoluble measures of OC over MOAB-2 may 
indicate that only a subset of aggregates, i.e. those rich in OC reactive fibrils, may be 
associated with bona fide disease relevant pathology.   
 
3.3 Correlation between pathological markers and cognitive scores 
In agreement with previous histopathological (Arriagada et al., 1992; Giannakopoulos et al., 
2003; Markesbery 2006) and biochemical studies (Näslund et al., 2000; Tremblay et al., 
2007), our initial findings indicated superior associations between soluble vs. insoluble 
markers and MMSE and CDR scores. Furthermore, tau-based pathology more robustly 
correlated with cognitive impairment than Aβ, independent of solubility. 
When considered across all Braak stages, all markers of tau pathology correlated to a 
varying degree with disease progression as well as with cognitive scores. However, levels of 
total insoluble tau (HT7) within the medial temporal gyrus failed to robustly track cognitive 
decline and insoluble measures of all tau markers reported a diminished relationship with 
ante-mortem cognition. The lack of predictive value of insoluble tau pathology is perhaps 
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unsurprising as numerous studies have reported the age-related deposition of tau within 
this area, without prominent cognitive impairment (Spires-Jones et al., 2017). Indeed, by 80 
years of age ~50% of individuals demonstrate pathology consistent with a classification of 
Braak stage 3 or 4 (Braak et al., 2011).  
A common feature of neuronal injury as well as aging, moderate tau pathology is observed 
following a variety of conditions with varying impact on cognitive faculties such as epilepsy 
(Thom et al., 2011) and subclinical chromic traumatic encephalopathy (McKee et al., 2012). 
This may further confound the relevance of broad-spectrum measures of tau in relation to 
cognitive decline. Accordingly, after exclusion of end stage cases with the highest levels of 
tau pathology, correlations between cognition and tau measures were lost.  
Though in many cases levels of both soluble and insoluble Aβ are reportedly elevated in AD 
cases compared to controls, correlations with symptoms are rarely observed (McLean et al., 
1999; Ingelsson et al., 2004; Tremblay et al., 2007). Tremblay and colleagues reported 
modest correlations of soluble and insoluble Aβ with cognitive scores, yet this was only 
specific to Aβ42, in contrast to our measures of total Aβ which tracked both cognitive scores 
and Braak staging. Here, the use of a N-terminal directed antibody (Youmans et al., 2012), 
rather than the frequently employed Aβ40 or Aβ42 C-terminal directed antibodies, may have 
provided improved specificity for the detection of a number of Aβ variants, potentially 
offering a more robust method of Aβ quantification. Nevertheless, insoluble measures of Aβ 
were weaker than the soluble measures, likely as a result of the extensive overlap of Aβ 
plaques seen between high pathological controls and demented individuals (Price and 
Morris, 1999).   
The generalised fibril antibody OC yielded improved correlations with cognitive scores, 
Braak staging and CERAD scores particularly in the insoluble fraction when compared to 
total Aβ. The apparent improved relevance of insoluble OC may relate to the increased 
specificity of the antibody, which detects amyloid fibrils with toxic potential, in contrast to 
total Aβ measures which may be confounded by the additional detection of non-toxic 
aggregates. These findings extend previous analyses of soluble OC reactive fibrillary 
oligomers within the entorhinal and frontal cortex, aligned with MMSE, Thal phase and 
Braak staging (Tomic et al., 2009). Our data suggest that both soluble and insoluble pools of 
fibrillary amyloid correlate with disease progression as well as cognitive impairment, it 
remains however unclear which species and compartments are causative for neuronal 
dysfunction. It is conceivable that such measures may merely be indices of progressive 
amyloid pathology rather than the principle toxic forms. Indeed, many animal models have 
demonstrated improved specificity for the emergence and elevation of A11 reactive 
prefibrillar Aβ species in conjunction with behavioural deficits, over that of OC reactive 
species (Lefterov et al., 2009; Liu et al., 2015; Chiang et al., 2017). 
Similar to that of tau pathology, measures of OC reactive species were dependent on late 
stage cases for correlation with cognitive decline and disease progression. In contrast 
  
16 
 
however soluble total Aβ remained highly correlated following the exclusion for end stage 
cases. The robustness of this relationship suggests soluble Aβ levels to be more indicative 
for early stage AD pathology than tau, at least in the temporal lobe.  
 
 
 
 
3.4 Limitations 
The current study is not without its limitations, most of which are relevant to post-mortem 
studies in general: Although the spread of tau and amyloid pathology is believed to 
represent a progressive scale, such a continuum cannot be thought of in relation to the 
diagnosis of AD. For moderate neuropathology cases (Braak stage 3 and 4), it is impossible 
to ascertain if such cases would have progressed to more advanced pathology and the 
ultimate diagnosis of AD. Hence, assumptions were made here regarding the progression of 
pathology between cases of likely differing status Similarly, the use of a single brain region 
(BA 21, lateral temporal cortex) precludes the generalisation of such relationships between 
soluble and insoluble pathology throughout the brain. Though relationships and equilibria 
are likely preserved across brain regions, a detailed multi-regional study is warranted. 
Furthermore, from post-mortem studies alone it is impossible to determine the causative 
contribution of each biochemically distinct species. These may merely be a consequence or 
by-product of degeneration, thus acting as a surrogate for neuronal injury potentially 
caused by other pathological cascades. 
As with all antibody based studies, the detection and identification of distinct pathological 
species relies on the specificity of the antibodies, lysis conditions and sample preparations 
(Kumar et al., 2008). Many studies, including our own, have highlighted the potential for 
modification of Aβ oligomerisation and immunoreactivity due to experimental procedures 
(Hepler et al., 2006; Pujol-Pina et al., 2015; Koss et al., 2016). As yet, no systematic study 
has been conducted into the consequences of experimental parameters for the detection of 
tau oligomers, although for example, the post-mortem interval likely alters levels of 
phosphorylation (Ferrer et al., 2007). Here, we employed native state dot blots to minimise 
sample exposure to denaturing factors and thus preserve conformational states. However, 
this is not without its own issues, as immunoreactivity within individual dots may represent 
multiple molecular species, distinct in molecular weight, which cannot be distinguished. 
Therefore, the protein detection achieved by native state dot blots likely include 
truncation/degradation products which retain epitope competent sequences.   A final 
consideration is that antigens may exist in alternative conformation/aggregation states in 
different lysis fractions, resulting in altered antibody affinity. This limitation is somewhat 
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addressed by reporting data relatively to controls within a specific fraction, although cross 
fractional comparison may be impacted due to varying antibody sensitivity.  
The use of additional techniques such as ELISAs and mass  spectrometry (MS) would allow 
for a more comprehensive profile of pathological proteomic changes to be reported. 
Specifically the characterisation of pathology would benefit from the determination of 
target protein species concentration rather than relatively changes from non-pathological 
conditions. A further advantage of MS is that it is not limited to target lead research and 
thus improves upon antibody based studies enabling the identification of unknown 
modifications and proteins within pathological tissue. 
3.5 Conclusions 
The present study builds upon prior post-mortem examination of AD brain tissue and serves 
to highlight different rates of tau and amyloid accumulation within the temporal lobe. The 
study provides evidence for site-directed tau phosphorylation and oligomerisation in 
promoting aggregation into insoluble structures. Equally, the quantification of selective Aβ 
species with established toxicity offers greater correlation with disease progression and 
cognitive decline than a generalised measure of Aβ, particularly within insoluble 
compartments whilst highlights soluble Aβ of potentially the most relevant to early stage 
changes.  
 
4. Methods 
4.1 Tissue samples 
Human tissue and metadata for this current study were supplied by the MRC London 
Neurodegenerative Diseases Brain Bank, The Thomas Willis Oxford Brain Collection, The 
Manchester Brain Bank, the Newcastle Tissue Resource and the South West Dementia Brain 
Bank and was overall co-ordinated via the Brains for Dementia (BDR) initiative. 
Human temporal cortex samples (n=46, middle temporal gyrus, Brodmann area 21) as 
previously reported (Koss et al., 2016) were used for the comparative investigation of AD 
relevant proteinopathy markers in NP40-lysis soluble and insoluble fractions.  Samples were 
received as 500 mg frozen blocks and stored at -80oC before processing.  Metadata included 
gender, age at death, post-mortem interval (PMI), cortical pH (were recorded) as well as 
clinical diagnosis in relation to AD (non-AD or AD) and neuropathological assessments; Braak 
stage (n=46) and CERAD neuritic plaque score (n=35) in addition to cognitive scores from the 
Mini Mental State Exam (MMSE; n=43) and Clinical Dementia Rating (CDR) global (n=44), 
memory (n=44) and sum of box scores (n=34) variants. Those cases with a clinical diagnosis 
of AD and consistent neuropathology (Braak stage ≥4) were considered as AD cases, non-AD 
cases comprised of those without a clinical diagnosis of AD nor related dementia’s and 
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whose neuropathological examination did not report any obviously signs of underlying 
neurological conditions. See Table 3 for summary. 
4.2 Brain lysate preparation 
Samples were processed as previously outlined (Koss et al., 2016). In brief, 100 mg of frozen 
tissue was manually homogenised in ~1:10 (w/v) modified NP-40/ Igepal based non-
denaturing, non-ionic lysis buffer (in mM: 20 HEPES, 150 NaCl, 0.1 EDTA, 1% Igepal, p.H 
=7.6) containing complete protease inhibitor (Roche) and PhosStop tablets (Roche). Samples 
were cleared of insoluble material via centrifugation (13,000 g, 4OC for 20mins) and 
supernatant collected as Igepal soluble material (referred to throughout as the soluble 
fraction). The resulting pellet was further homogenised twice in lysis buffer (1ml) and spun 
(13,000 g, 4OC for 20mins) prior to resuspension and overnight incubation with agitation in 
1:1 (w/v) 70% formic acid at 4OC. The formic acid suspension was spun (18,000 g, 4OC for 
20mins) and the supernatant collected (referred to throughout as the insoluble fraction) and 
stored at -80OC. Prior to use the insoluble fraction was mixed in 4 volumes of neutralising 
buffer (2M Tris + 2M NaH2PO4).  
4.3 Immuno-blots 
For soluble fractions protein concentration was established via bicinchoninic acid assay 
(BCA, Sigma-Aldrich, Poole, UK) and adjusted to the desired concentration via sample 
dilution in lysis buffer. Due to the strong reducing action of formic acid the determination of 
protein concentration via standard protein quantification methods was not possible for the 
insoluble fraction and as such a set volume of neutralised samples was used. Nevertheless, 
all immuno-blot signals were adjusted via a Coomassie total protein stain (see below).   
Both fractions were subject to standard Western blot and dot blot protocols (as described in 
Koss et al., 2016). For Western blotting, all samples were mixed with lithium dodecyl 
sulphate (LDS, Nupage, Thermo Fisher Scientific, Paisley, UK) and 15 mM dithiothreitol (DTT, 
Sigma), heated at 70OC for 10mins prior to being run (20 µg/lane of soluble fraction and 10 
µl/lane for neutralised insoluble samples) on 4-12% Bis-Tris precast gels (Nupage, Thermo 
Fisher Scientific). For Aβ and fibrillary amyloid detection, samples were separated for 35 
mins in MES buffer and for tau for 45 mins in MOPS buffer at 200 V constant voltage. 
Proteins were then either transferred to 0.2 µm nitrocellulose membranes via the IBlot 
system, followed by microwaving for 3 mins in PBS or to 0.45 µm nitrocellulose membranes 
via standard transfer conditions for tau. 
For dot blots, samples were dotted directly to 0.2 µm nitrocellulose membranes (5 µl of 2 
µg/µl per dot for soluble and 5 µl of neutralised insoluble samples), without the addition of 
LDS or DTT or heating.  
All blots were washed in 0.05% Tween-20 (Sigma) containing Tris-buffered saline (TBST, in 
mM; 50 Trizma base, 150 NaCl, pH=7.6) before being blocked for 1hr at room temperature 
in TBST containing 5% milk power and subsequently incubated overnight at 4oC with the 
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relevant antibodies (see Table 4 for details) in 5 % bovine serum albumin containing TBST + 
0.05 % Na-Azide (Sigma). Primary antibodies were labelled with appropriate secondary 
antibodies conjugated to horse radish peroxidase (1hr, room temperature in TBST + 5% milk 
powder + 1:5000, goat anti-rabbit or anti-mouse secondary antibodies IgG/ IgM isotypes). 
Immunoreactivity was visualised via enhanced chemiluminescence (1.25mM Luminol, 30µM 
coumaric acid and 0.015% H202) and captured with use of a Vilber-Fusion- SL Camera (Vilber, 
Eberhardzell, Germany). The exposure time for each individual blot was determined by 
Fusion software (Vilber, Eberhardzell, Germany) auto-exposure function ensuring no pixel 
saturation. The resulting images were saved as 8 bit for illustration and 16 bit for 
quantification. 
After capture of immunoreactivity, blots were processed for total protein following a 
standard Coomassie protein stain (as described previously Koss et al., 2016). 
4.4 Immuno-blot quantification 
ECL images and Coomassie labelled protein stains were quantified using area under curve 
(AUC) measurements as calculated by ImageJ (Ver 1.47, NIH, USA). ECL values were adjusted 
for total protein load as per Coomassie stained membranes and normalised within blots to 
one of three analytical classifications (also see Koss et al., 2016): 
1. Post-mortem confirmed clinical diagnosis, eg. Non-AD cases (i.e. Braak 0-3) and AD cases 
(i.e. Braak 4-6).  Normalisation conducted to mean intensity of Non-AD cases within blots. 
2. Grouped Braak stages: low, intermediate and high severity of Braak pathology (Braak 0-2, 
Br 3-4 and Br 5-6, respectively). Normalisation conducted to mean intensity of low 
neuropathology  cases within blots. 
3. Individual Braak scores: cases separated into individual stages. Normalisation conducted 
to mean intensity of Braak stage 2 cases within blots. 
 
4.5 Statistical analysis 
All 46 human case samples were probed for all markers in both soluble and insoluble 
fraction-based dot blots. Samples were run in fixed batches (4 batches; containing 10-16 
samples) and normalisation (as outlined above) conducted within blots, prior to pooling 
data between batches, such that all measures reported here are compiled from all cases. All 
statistical analysis was conducted using Graphpad Prism (ver 5.04). Normal distribution 
was probed via the Shaprio-Wilk test. Comparative analysis was subsequently preformed 
using either a Student’s two tailed t test or its non-parametric equivalent (Mann-Whitney U 
test) to compare two data sets. Multiple group comparisons were performed via a 1-way 
analysis of variance (ANOVA) or Kruskal-Wallis ANOVA with selected post-hoc paired 
comparisons via  Bonferroni or Dunn’s test. Two variable multi-group comparisons were 
conducted using 2-way ANOVA and bonferroni post-tests where appropriate. Correlations 
were determined via Spearman’s Rank correlation coefficient. Correlations presented in 
Table 1 and 2 were adjusted for multiple comparisons using a Bonferroni correction to α, i.e. 
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α=1-(1-0.005) and 1-(1-0.003571), respectively. In order to maintain consistency of statistical 
reporting e.g. (p<0.05), p values are reported as 1-(1-[p/10])10 and 1-(1-[p/14])14 in Table 1 
and 2, respectively. 
For correlations with Braak staging, significant outcomes were further probed via a one-
tailed t-test to determine the initial stage for a significant deviation from pathology-free 
Braak 0 cases. For all analysis, p<0.05 was regarded as reliable with further statistical 
strength observed for p<0.01, p<0.001 and p<0.0001. 
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Figure legends 
Figure 1. SDS page identification of distinct soluble and insoluble tau, Aβ and amyloid species. 
Example Western blot images resulting from probing of soluble (Sol) and insoluble (InSol) lysates 
from control (con) and AD cases with total tau antibody HT-7 (a), phospho-tau antibodies CP13 (b) 
and PHF1 (c), Aβ antibody MOAB (d) and the fibrillary amyloid antibody OC (e). Corresponding Braak 
stage (Br) classifications for each sample are shown above each lane and molecular weight marker 
with weights in kDa shown for orientation. 
 
Figure 2. Soluble and insoluble tau.  Soluble (Sol) and Insoluble (Insol) total tau (HT-7) dot blots (i) in 
cases labelled as Alzheimer's disease (AD) and control (C) cases and corresponding Braak stage (Br). 
Analysis of reactivity normalised to total protein stratified for (ii) diagnosis, neuropathology severity 
(iii, Low; Br 0-2, Intermediate (Inter); Br 3-4 and High; Br 5-6) and correlated with individual Br stage, 
with Spearman’s correlation (r) reported in legend (iv). Pooled data obtained from 4 independent 
batches of blots each with different cases (n=46 total) are presented as scatter plots and mean ± 
SEM in ii + iii and as mean + / - SEM in iv.  Statistical significance is indicated as **=p<0.01, 
***=p<0.001 and ****=p<0.01. $ denotes earliest Braak stage at which the signal is significantly 
elevated from pathology free cases (Br 0). 
 
Figure 3. Soluble and insoluble phospho tau pathology; Soluble (Sol) and Insoluble (Insol) dot blots 
for AT8 (a), CP13 (b) and PHF-1 (c) reactive phospho tau (i). Samples are indicated as Alzheimer's 
disease (AD) and control (C) cases with assigned Braak stage (Br). Immunoreactivity adjusted for 
total protein quantified according to diagnosis (ii), neuropathology severity (iii, Low; Br 0-2, 
Intermediate (Inter); Br 3-4 and High; Br 5-6) and individual Br stage, Spearman’s correlation (r) 
reported in legend (iv). Scatter plots depict data obtained from 4 independent blots of cases run in 
batches (n=46 total cases). Mean ± SEM values are present in ii + iii and mean + / - SEM in iv.  
Statistical outcomes are denoted **=p<0.01, ***=p<0.001 and ****=p<0.0001. $ indicates the 
earliest Braak stage at which the signal is significantly elevated from pathology free cases (Br 0).  
 
Figure 4. Soluble and insoluble oligomeric tau; Soluble (Sol) and Insoluble (Insol) dot blots for tau 
oligomeric complex 1 (TOC1) immunoreactivity (i). Samples are indicated as Alzheimer's disease (AD) 
and control (C) cases with assigned Braak stage (Br). Quantified signal intensity normalised against 
total protein Coomassie stain shown as per diagnosis (ii), severity of neuropathology (iii; low; Br0-2, 
intermediate (inter); Br 3-4 and high; Br 5-6) and individual Braak stage (iv) stratifications. Data 
pooled from 4 blots containing different cases (n=46 total cases) presented as scatter plots with 
mean ±SEM (ii+iii)/ mean + or – SEM and Spearman’s correlation (r) stated in the legend (iv).  as 
**=p<0.01,***=p<0.001 and ****=p<0.0001.  $ denotes the initial Braak stage at which quantified 
signal is significantly elevated from Braak stage 0.   
 
Figure 5. Soluble and insoluble β amyloid; Dot blots for total Aβ stained with the MOAB-2 antibody. 
Alzheimer's disease (AD) and control (C) cases and corresponding Braak stage (Br) are indicated. 
Immunoreactivity adjusted for total protein as per Coomassie stain quantified according to diagnosis 
(ii), severity of neuropathology (iii; low; Br0-2, intermediate (inter); Br 3-4 and high; Br 5-6) and 
individual Braak stage (iv) is shown. Scatter plots of pooled data from 4 batches of blots (n=46 total 
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cases) with mean ±SEM indicated are presented in ii+iii and mean + or – SEM in iv with Spearman’s 
correlation (r) noted in the legend.  Statistical comparisons are indicated as *=p<0.05, ***=p<0.001 
and ****=p<0.0001. $ denotes the initial Braak stage at which quantified signal is significantly 
elevated from Braak stage 0. NS = not significant.  
 
 
Figure 6. Soluble and insoluble fibril amyloid; Soluble (Sol) and Insoluble (Insol) dot blots for amino 
acid sequence independent fibril amyloid as detected via the OC antibody. Cases are noted as 
Alzheimer's disease (AD) and control (C) cases alongside Braak stage (Br).  Quantification of cohort as 
normalised to total protein and subsequently diagnosis (ii), severity of neuropathology (iii; low; Br0-
2, intermediate (inter); Br 3-4 and high; Br 5-6) and individual Braak stage (iv) is shown. Individual  
normalised data for each case is presented in  scatter plots (n=46 total cases) with mean ±SEM 
indicated in ii+iii and as Braak stage mean + or – SEM in iv with Spearman’s correlation (r) noted in 
the legend.  Statistical comparisons are indicated as *=p<0.05, **=p<0.01, ***=p<0.001 and 
****=p<0.0001. $ denotes the initial Braak stage at which quantified signal is significantly elevated 
from Braak stage 0.   
 
 
Table legends 
Table 1: Correlation of tau and amyloid pathology. Correlation between soluble (sol) and insoluble 
(Insol) pathology. Spearman correlations (r) between measures of tau markers [Total tau (HT7), 
phospho-tau (AT8, CP13 and PHF1) and oligomeric tau (TOC1)] and amyloid markers [total Aβ 
(MOAB-2) and fibril amyloid (OC)] are reported. Significance (all p<0.05) are reported here was 
subject to bonferroni corrections for multiple comparisons. NS= not significant. 
Table 2: Tau and amyloid pathology correlations with neuropathological staging schemes and 
cognitive scores. Soluble (s) and insoluble (I) tau [ Total tau (HT7), phospho-tau (AT8, CP13 and 
PHF1) and oligomeric tau (TOC1)] and amyloid total Aβ (MOAB-2) and fibril amyloid (OC)] markers 
are presented. Spearman’s rank correlations (r) between Braak staging and CERAD 
neuropathological scores as well as cognitive scores as assessed by the mini mental state exam 
(MMSE) and clinical dementia rating (CDR) alongside CDR memory and sum of boxes (SOB). Values 
given in brackets report correlations obtained following the exclusion of end stage Braak stage 5/6 
pathological cases. Strength of statistical significance following bonferroni corrections for multiple 
comparisons are shown where *=p<0.05, **=p<0.01, ***=p<0.001 and ****=p<0.0001 and NS= not 
significant. 
Table 3: Biographical and pathological data of cohort. Cases are organised according to analytical 
stratifications (diagnosis, neuropathological severity and individual Braak stage). CERAD neurtic 
plaque score, sample size (N), gender composition (% males) and the mean ± SEM and range of age, 
post-mortem interval (PMI) and cortical pH are provided.  
Table 4 Antibodies. Commercial names, epitope, specificity, dilution and supplier are given for 
antibodies used in the study. Phospho-epitopes for antibodies are provide with phosphorylated (p) 
residues listed as either Serine (Ser) or Threonine (Thr), amino acid (aa) sequences given according 
to the longest isoform.    
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MOAB-2 OC 
Marker Solubility Sol Insol Sol Insol 
HT7 
Sol 0.5 NS 0.6 0.41 
Insol NS NS 0.6 NS 
AT8 
Sol 0.7 NS 0.7 0.44 
Insol 0.46 NS NS NS 
CP13 
Sol 0.63 NS 0.7 0.56 
Insol 0.54 NS 0.49 0.49 
PHF1 
Sol 0.67 NS 0.65 0.5 
Insol 0.5 NS 0.68 0.53 
TOC1 
Sol 0.52 NS 0.58 0.41 
Insol 0.4 NS 0.6 0.56 
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Solubility Braak CERAD MMSE CDR CDR memory CDR SOB 
Tau 
Total 
[HT-7] 
S 
**r=0.72   
(NS) 
**; r=0.76 
(NS) 
*; r=-0.55 
(NS) 
**; r=0.56 
(NS) 
**; r=0.59 
(NS) 
*; r=0.52 
(NS) 
I 
**r=0.57 
 (NS) 
NS 
(NS) 
NS 
(NS) 
NS 
(NS) 
NS 
(NS) 
NS 
(NS) 
Phospho 
 [AT-8] 
S 
**; r=0.81 
(**; r=0.71) 
**; r=0.79 
(NS) 
**; r=-0.67 
(NS) 
**; r=0.69 
(NS) 
**; r=0.7 
(NS) 
**; r=0.63 
(NS) 
I 
**; r=0.75 
(NS) 
*; r=0.52 
(NS) 
*; r=-0.37 
(NS) 
*; r=0.36 
(NS) 
NS 
(NS) 
NS 
(NS) 
Phospho 
[CP13] 
S 
**; r=0.78 
(**; r=0.65) 
**; r=0.72 
(NS) 
**; r=-0.68 
(NS) 
**; r=0.69 
(NS) 
**; r=0.71 
(*; r=0.56) 
**; r=0.67 
(NS) 
I 
**; r=0.65 
(NS) 
**; r=0.66 
(NS) 
**; r=-0.67 
(NS) 
**; r=0.69 
(NS) 
**; r=0.63 
(NS) 
*; r=0.59 
(NS) 
Phospho 
[PHF-1] 
S 
**; r=0.83 
(**=; r=0.66) 
**; r=0.74 
(NS) 
**; r=-0.70 
(NS) 
**; r=0.68 
(NS) 
**; r=0.72 
(NS) 
*; r=0.55 
(NS) 
I 
**; r=0.83 
(**; r=0.83) 
**; r=0.80 
(*;r=0.8) 
**; r=0.69 
(NS) 
**; r=0.68 
(NS) 
**; r=0.67 
(NS) 
*; r=0.66 
(NS) 
Oligomeric 
[TOC1] 
S 
**; r=0.60 
(NS) 
**; r=0.62 
(NS) 
**; r=-0.59 
(NS) 
**; r=0.62 
(NS) 
**; r=0.62 
(NS) 
*; r=0.57 
(NS) 
I 
**; r=0.61 
(NS) 
**; r=0.65 
(NS) 
*; r=-0.54 
(NS) 
*; r=0.53 
(NS) 
*; r=0.5 
(NS) 
*r=0.49 
(NS) 
 
Amyloid 
Aβ Total 
[MOAB-2] 
S 
**; r=0.70 
(*; r=0.53) 
**; r=0.69 
(NS) 
**; r=-0.69 
(*; r=-0.58) 
**; r=0.71 
(**; r=0.70) 
**; r=0.61 
(*; r=0.53) 
NS 
(NS) 
I 
NS 
(NS) 
NS 
(NS) 
NS 
(NS) 
*; r=0.49 
(*; r=0.6) 
NS 
(NS) 
NS 
(NS) 
 Fibril 
amyloid 
 [OC] 
S 
**; r=0.68 
(NS) 
**; r=0.67 
(NS) 
**; r=-0.58 
(NS) 
**; r=0.63 
(NS) 
**; r=0.62 
(NS) 
*; r=0.52 
(NS) 
I 
**; r=0.58 
(NS) 
**; r=0.60 
(NS) 
**; r=-0.54 
(NS) 
**; r=0.59 
(*; r=0.6) 
*; r=0.55 
(NS) 
NS 
(NS) 
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Braak 
stage 
CERAD N Male (%) 
Mean Age 
(years) 
Age range 
(years) 
Mean PMI 
(hrs) 
PMI range 
(hrs) 
Mean 
cortical pH 
Cortical pH 
range 
Diagnosis 
Non-AD 0-3 C0-C2 27 44.4 86 ± 1.4 74-103 44.9 ± 5.2 11-110 6.3 ± 0.1 5.4-6.9 
AD 4-6 C2-C3 19 60 83.4 ± 1.2 71-90 46.6 ± 4.9 20-87 6.3 ± 0.1 6-6.9 
Neuropathological severity 
Low 0-2 C0-C1 18 66.7 85.3 ± 1.9 74-103 40.7 ± 6.2 11-92 6.3 ± 0.1 6-6.7 
Inter 3-4 C0-C3 14 28.6 85.9 ± 1.5 77-95 51.5 ± 7 13.5-101 6.2 ± 0.2 5.4-6.9 
High 5-6 C1-C3 14 71.4 83.6 ± 1.5 71-90 46 ± 5.7 20-78 6.4 ± 0.1 6.1-6.9 
Braak stage 
 
0 C0 3 100 76.7 ± 1.3 74-78 30 ± 13.5 11-56 6.1 ± 0.1 6-6.1 
 
1 - 0 - - - - - - - 
 
2 C0-C1 15 40 87 ± 2 74-103 42.8 ± 7 12-92 6.3 ± 0.1 6-6.7 
 
3 C0-C2 9 33.3 87.6 ± 1.7 78-95 53.4 ± 9.5 13.5-101 6.2 ± 0.3 5.4-6.9 
 
4 C2-C3 5 40 82.8 ± 2.2 77-88 48.2 ± 10.6 26-87 6.2 ± 0.2 6.0-6.8 
 
5 C1-C3 6 83.3 83.8 ± 1.2 82-88 50.5 ± 10.1 22-78 6.3 ± 0.1 6.1-6.6 
 
6 C3 8 50 83.5 ± 2.4 71-90 42.6 ± 6.9 20-69 6.5 ± 0.1 6.3-6.9 
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Antibody Epitope Specificity Dilution Supplier 
HT7 aa 159-163 of tau Pan-tau 1:5000 Autogen Bioclear 
AT8 pSer199/202 +pThr205 Phospho-tau 1:50 Autogen Bioclear 
CP13 pSer202 Phospho-Tau 1:250 P.Davies Lab 
PHF-1 pSer396/404 Phospho-Tau 1:1000 P.Davies Lab 
TOC1 epitope preferentially exposed 
when oligomerised; aa 209-244 
Oligomeric Tau 1:5000 N. Kanaan / L. 
Binder Lab 
6E10 aa 3-8 of Aβ 
APP and 
metabolites (Aβ) 
1:1000 Biolegend 
MOAB-2 aa 1-4 of Aβ Aβ only 1:1000 Biosensis 
OC 
sequence independent, 
conformational epitope  
Amyloid fibrils 
1:1000 Millipore 
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Highlights 
 Two distinct phospho-dependent profiles of insoluble tau deposition are apparent.  
 Soluble tau and Aβ better correlate with AD progression than insoluble measures. 
 Soluble tau and Aβ better correlate with cognitive decline than insoluble measures. 
 Soluble Aβ correlate with cognitive decline following end stage case exclusion.  
 Insoluble fibril amyloid better correlates with AD progression than total Aβ.    
 
